



1 / 14

SEQ ID NO:1

MTQDCSFQHS PISSDFAVKI RELSDYLLQD YPVTVASNLQ
DEELCGGLWR LVLAQRWMER LKTVAGSKMQ HFVTKCAFQP
PPSCLRfvQT NISRLLQETS EQLVALKPWI TRQNFSCLE
LQCQPDSSTL PPPWSPRPLE ATAPTA

FIG._1

SEQ ID NO:2

MEGICRNRVT NNVKDVTKLV ANLPKDYM IT LKYVPGMDVL
PSHCWISEMV VQLSDSLTDL LDKFSNISEG LSNYSIIDKL
VNIVDDLVEC VKENSSKDLK KSFKSPEPRL FTPEEFFRIF
NRSIDAFKDF VVASETSDCV VSSTLSPEKD SRVSVTKPFM
LPPVA

FIG._2

SEQ ID NO:3

PVPPGEDSKD VAAPHRQPLT SSERIDKQIR YILDGISALR
KETCNKSNMC ESSKEALAEN NLNLPKMAEK DGCFQSGFNE
ETCLVKIITG LLEFEVYLEY LQNRFESSEE QARAVQMSTK
VLIQFLQKKA KNLDAITTPD PTTNASLLTK LQAQNQWLQD
MTTHLILRSF KEFLQSSLRA LRQM

FIG._3

SEQ ID NO:4



MHKCDITLQE IIKTLNSLTE QKTLCTELTV TDIFAASKNT
TEKETFCRAA TVLRQFYSHH EKDTRCLGAT AQQFHRHKQL
IRFLKRLDRN LWGLAGLNSC PVKEANQSTL ENFLERLKTI
MREKYSKCSS

FIG._4

SEQ ID NO:5

MAPMTQTTSL KTSWVNCSNM IDEIITHLKQ PPLPLDFNN
LNGEDQDILM ENNLRRPNLE AFNRAVKSLQ NASAIESILK
NLLPCLPLAT AAPTRHPIHI KDGDWNEFRR KLTFYLKTLE
NAQAAQQTTLAIF

FIG._5

**FIG._6A****FIG._6B**




FIG. 7A-1

FIG. 7A-1 **FIG. 7A-2** **FIG. 7A-3**

FIG. 7A





FIG. 7A-2

**FIG.- 7A-3**





FIG. 7B-1

FIG. 7B-1 FIG. 7B-2 FIG. 7B-3

FIG. 7B

**FIG. - 7B-2**




FIG._7B-3



CHMC.3
"unprimed"CHMC.3
"primed"**FIG.-7C-1**

FIG.-7C-1 FIG.-7C-2 FIG.-7C-3

FIG.-7C

10 / 14







CHMC.3
"unprimed"CHMC.3
"primed"

FIG. 7C-2



**FIG._8A****FIG._8B****FIG._8C****FIG._8D**




FIG._8E




FIG._8F




FIG._8G

CD Profile Summary For CHMC's**A**CD15, CD11b, and CD13:

CD15 pos:	3%
CD11b pos:	0%
CD13 pos:	35%
CD15/13 pos:	3%
CD11b/13 pos:	2%
CD11b/15pos:	1%
CD15/13 neg:	55%
CD11b/13 neg:	59%
CD11b/15 neg:	92%

CCD15, CD11b, and CD14:

CD15 pos:	4%
CD11b pos:	0%
CD14 pos:	39%
CD15/14 pos:	4%
CD11b/14 pos:	2%
CD11b/15pos:	0%
CD15/14 neg:	53%
CD11b/14 neg:	56%
CD11b/15 neg:	91%

BCD34, CD11b, and CD13:

CD34 pos:	0%
CD11b pos:	0%
CD13 pos:	32%
CD34/13 pos:	1%
CD11b/13 pos:	1%
CD11b/15pos:	0%
CD34/13 neg:	66%
CD11b/13 neg:	66%
CD11b/34 neg:	97%

DCD34, CD11b, and CD14:

CD34 pos:	0%
CD11b pos:	0%
CD14 pos:	37%
CD34/14 pos:	0%
CD11b/14 pos:	2%
CD11b/34pos:	0%
CD34/14 neg:	58%
CD11b/14 neg:	58%
CD11b/34neg:	96%

FIG._9